AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764

/in
  • ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome
  • Preliminary data showed ACI-19764 was safe and well tolerated across single and multiple ascending dose cohorts with confirmed CSF penetration
  • Based on PK data the therapeutic dose is expected to be ≤10mg once daily
  • To rapidly evaluate the anti-inflammatory activity of ACI-19764 (effect on hsCRP), dosing of a cardiovascular risk cohort is now underway with initial results expected by year end
  • Full results from the Phase 1/1b trial are expected in H1 2027
 
Lausanne, Switzerland, August 20 2026 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today announced positive interim results from a Phase 1 first-in-human clinical study evaluating ACI-19764, its wholly-owned, orally administered small molecule inhibitor of the NLRP3 inflammasome.
© Optimum Strategic Communications.
Hansa Biopharma announces first commercial kidney transplant patient treated...Hansa Biopharma Announces Confidential Submission of Draft Registration Statement...